Blood Res.  2014 Mar;49(1):3-4. 10.5045/br.2014.49.1.3.

How do we prepare ourselves for a new paradigm of medicine to advance the treatment of pediatric acute lymphoblastic leukemia?

• Park KD

• KMID: 2172814
• DOI: http://doi.org/10.5045/br.2014.49.1.3

Abstract

No abstract available.

MeSH Terms

Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Reference

1. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6:224ra25.

2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29:551–565. PMID: 21220611.

3. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013; 381:1943–1955. PMID: 23523389.

4. Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012; 68:1233–1242. PMID: 22421815.

5. Yeoh AE, Ariffin H, Chai EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012; 30:2384–2392. PMID: 22614971.

6. Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 2013; 14:e508–e523. PMID: 24176570.

7. Jang MJ, Park HJ, Yoon SS, et al. Health insurance system for hematologic diseases: what should we do? Korean J Hematol. 2011; 46:6–8. PMID: 21461295.